Learn More

Targeted Radioisotope Therapy Webinar Series

The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.

Healthcare Provider

Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.

What are Nuclear Medicine and Molecular Imaging?

Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures—such as x-rays, computed tomography (CT) and ultrasound—offer pictures of physical structure, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.

Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can also be used to treat certain types of cancer and  other diseases.

Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:

  • provide information that is unattainable with other imaging technologies or that would require more invasive procedures such as biopsy or surgery
  • identify disease in its earliest stages and determine the exact location of a tumor, often before symptoms occur or abnormalities can be detected with other diagnostic tests

Learn More

 

Disease-Specific Information

Oncology

Cancer Scan

Cardiology

Heart Scan

Neurology

Brain Scan

Guidance

SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.

Guidelines
Appropriate Use Criteria
Dosimetry
Dose Optimization

Related Resources

NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary

Ordering Information

The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:

  • Sample Request Forms
  • Sample Letters of Medical Necessity
  • Sample Reports from Nuclear Medicine Physician
  • CMS Decision Memos

Learn More

Request a Speaker

SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.

Outreach Speaker Request Form
Outreach Program
FAQs

 

 

  • May 4, 2015Travel Update

    SNMMI is happy to report that Baltimore is now calm, and things are returning to normal. The Inner Harbor area, where the SNMMI Annual Meeting will take place, was never affected by the unrest. SNMMI is looking forward to a great meeting June 6-10.
    (SNMMI News)

  • May 4, 2015Recurrence of Prostate Cancer Detected Earlier with Innovative PSMA-ligand PET/CT

    May 4, 2015 - A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy. Discovering a recurrence early can strongly influence further clinical management, so it is especially noteworthy that this hybrid PSMA-ligand identified a large number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL).
    (Press Release)

  • April 30, 2015Study: PET with lapatinib zeroes in on brain metastases

    Brain metastases are common in human epidermal growth factor receptor (Her)-2-positive breast cancer. Drug access to brain metastases and normal brain is key to management of cranial disease.
    (MI: Making a Difference)

  • April 30, 2015The multi-pronged approach to reducing MPI dose

    The use of myocardial perfusion imaging (MPI) has spiked over the past four decades and along with it individual patient dose. A comprehensive effort to reduce that dose could reduce unnecessary procedures and reduce the risk of downstream cancers, according to a meta-analysis published in the April issue of the Journal of Nuclear Medicine.
    (MI: Making a Difference)

  • Jun 6, 2015 -  Jun 10, 2015 SNMMI 2015 Annual Meeting
    Baltimore Convention Center Headquarter Hotel: Hilton Baltimore | Baltimore | USA

Featured Resources

  • Annual Reports

  • Journals

    Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.

  • Guidance

    Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.

  • 2014 NCI-SNMMI Workshop on Targeted Radionuclide Therapy

    The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) held a joint workshop—NCI-SNMMI Workshop on Targeted Radionuclide Therapy—on October 24-25, 2014, at the National Institutes of Health (NIH) in Bethesda, Md.

  • 2015 Nuclear Medicine & PET Coder